The Patent Finder

Imcyse S.A.

Also on record
Records under this name other than the patents Imcyse S.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 12 patents it holds.

Showing 1 to 9 of 9 · Back to Imcyse S.A.

PatentTitleStatus Expires Confidence
US 10,808,016Peptides and Methods for the Treatment of Diabetes
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,407,795Peptides and Methods for the Treatment of Diabetes
Formerly held
In force
 · High confidence
In forceHigh confidence
US 11,760,782Peptides and Methods for the Treatment of Diabetes
Formerly held
In force
 · High confidence
In forceHigh confidence
US 10,023,847Immunogenic Peptides for Use in the Prevention And/Or Treatment of Infectious Diseases, Autoimmune Diseases, Immune Responses to Allofactors, Allergic Diseases, Tumors, Graft Rejection and Immune Responses Against Viral Vectors Used for Gene Therapy or Gene Vaccination
Lapsed on the fee record
Ended Jul 17, 2026 · High confidence
Lapsed on the fee recordEnded Jul 17, 2026High confidence
US 11,226,332Method for the detection, preparation and depletion of CD4+ t lymphocytes
Lapsed on the fee record
Ended Jan 18, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jan 18, 2026From the USPTO record
US 9,861,661Elimination of immune responses to viral vectors
Lapsed on the fee record
Ended Jan 9, 2026 · From the USPTO record
Lapsed on the fee recordEnded Jan 9, 2026From the USPTO record
US 11,193,114Immunogenic Peptides for Use in the Prevention And/Or Treatment of Infectious Diseases, Autoimmune Diseases, Immune Responses to Allofactors, Allergic Diseases, Tumors, Graft Rejection and Immune Responses Against Viral Vectors Used for Gene Therapy or Gene Vaccination
Lapsed on the fee record
Ended Dec 7, 2025 · High confidence
Lapsed on the fee recordEnded Dec 7, 2025High confidence
US 10,982,196Immunotherapy targeting intracellular pathogens
Lapsed on the fee record
Ended Apr 20, 2025 · From the USPTO record
Lapsed on the fee recordEnded Apr 20, 2025From the USPTO record
US 10,899,795Modified epitopes for boosting CD4+ T-cell responses
Lapsed on the fee record
Ended Jan 26, 2025 · From the USPTO record
Lapsed on the fee recordEnded Jan 26, 2025From the USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited